I think we will see 2 or 3 dose escalation cohorts completed and reported over the next 6-9 months and then the trial will move onto the efficacy stage.
We know how well Bisantrene works for R/R AML as a single agent which bodes well for this trial. Average complete response of this group of Phase II trials = 51.6%.
Two french girls achieved long-term survival after treatment with Bisantrene Combination Therapy.
https://www.raceoncology.com/wp-content/uploads/2020/08/PBC-060818-Bisantrene-Combo-Poster.pdf
Ann: First Patient Dosed in Phase 1b/2 AML Trial, page-12
-
- There are more pages in this discussion • 234 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3105 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.95 | 7574 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |